Ashwanth Christopher Francis

The paper characterizes structural, biophysical, and virological properties of HIV-1 capsid-targeting antivirals, showing improved potency and stability through chemical modifications of PF74.

This study shows that cyclophilin A inhibits HIV-1 nuclear entry in mutants by reducing capsid elasticity, which is reversed by suppressor mutations.

This paper investigates how the M66I mutation in HIV-1 capsid protein confers resistance to lenacapavir by altering inhibitor binding and viral replication.

This study identifies the mechanism by which lenacapavir inhibits HIV-1 maturation by altering capsid protein assembly.

This study shows that HIV-1 core elasticity is essential for nuclear entry and infection, with capsid-targeting drugs reducing elasticity and impairing infectivity.